Copyright © 2019. Inderes Oy. All rights reserved.
Search
User account

Hei!

Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.

Oliko sinulla jo tili?

Log in
Revenio Group
4905 investors follow this company
BUY 24.60 LOWEST 24.60 VOLUME 20 012
SELL 24.65 HIGHEST 25.15 VALUE 0,495 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Latest reports

Extensive report

Analyytikko

Mikael Rautanen
+358 50 346 0321

Latest video

Latest insider trading

Type: stock_exchange_release
27.11.
2019

Notice pursuant to chapter 9, section 5 of the securities market act 

Revenio Group Corporation has November 24, 2019 received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that William Demant Invest A/S's share of the total number of shares and voting rights in Revenio Group Corporation has increased to more than five per cent.

William Demant Invest A/S now holds 2.192.838 shares in Revenio Group Corporation, which is 8.28 per cent of the company's shares and voting rights.

Type: stock_exchange_release
27.11.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Gerako Oy
Position: Closely associated person
(X) Legal person

(1):Person Discharging Managerial Responsibilities In Issuer
Name: Kohonen Ari
Position: Member of the Board

Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191127081924_2
____________________________________________

Type: stock_exchange_release
25.11.
2019

REVENIO'S CEO CHANGES - TIMO HILDÉN APPOINTED AS ACTING CEO

Revenio Group Cororation's ("Revenio", "Group") Board of Directors and CEO Mikko Moilanen have mutually agreed that Mikko Moilanen leaves his position as the CEO of the Group. The resignation shall take effect immediately.

Revenio's Board of Directors has appointed Timo Hildén as the acting CEO. He has worked as Revenio Group's CEO during January 1st, 2017 until July 30, 2019 as well as Revenio's Group company Icare Finland Oy's Managing Director during 2012-2017.

Type: stock_exchange_release
11.11.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Isomäki Ari
Position: Other senior manager
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191111104724_2
____________________________________________

Type: stock_exchange_release
11.11.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Tammela Pekka
Position: Member of the Board/Deputy member
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191111104323_2
____________________________________________

Type: stock_exchange_release
7.11.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Karvo Tomi
Position: Other senior manager
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191107144616_2
____________________________________________

Type: stock_exchange_release
5.11.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Isomäki Ari
Position: Other senior manager
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191105143353_2
____________________________________________

Type: stock_exchange_release
4.11.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Pulkkinen Robin
Position: Chief Financial Officer
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191104131119_2
____________________________________________

Type: stock_exchange_release
4.11.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Karvo Tomi
Position: Other senior manager
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191104130607_2
____________________________________________

Type: stock_exchange_release
28.10.
2019

Revenio Group Corporation - Managers' Transactions
____________________________________________

Person subject to the notification requirement
Name: Robin Pulkkinen
Position: Chief Financial Officer
(X) Legal person
Issuer: Revenio Group Corporation
LEI: 743700I27E0FWSXLKK04

Notification type: INITIAL NOTIFICATION
Reference number: 743700I27E0FWSXLKK04_20191028150106_2
____________________________________________

Revenio Group

Revenio lyhyesti

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio’s business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio’s screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.